Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Reform Using Part D Model Is Advocacy Priority For PhRMA – Castellani

Executive Summary

For PhRMA, supporting a move toward privatizing Medicare is a tactic that may help avoid the establishment of new price controls in the system, like the often-discussed mandated drug rebates in Part D.

You may also be interested in...

Ways And Means’ Legislative Priorities In Health: Medicare Structural Reform, SGR Repeal

Rep. Kevin Brady, new chairman of the House panel’s Health Subcommittee, says he will move ahead with a premium support system for Medicare, an approach to reform favored by PhRMA. Savings generated by that change will offset the cost of repealing the sustainable growth rate formula for Medicare physician payments.

Key House Medicare Subcommittee Will Have New Leaders; Rep. Stark Loses Election Bid

Rep. Pete Stark, D-Calif., often a critic of the pharmaceutical industry, lost his re-election bid, leaving the top Democratic spot open on the Ways and Means Committee’s Health Subcommittee. Subcommittee Chairman Wally Herger already planned to retire. All members of the Senate HELP and Finance Committees up for re-election won their races.

HHS’ Sebelius Takes Up Gauntlet Against Medicare Overhaul

In her appearance at the convention in Charlotte, N.C., on Sept. 4, HHS Secretary Kathleen Sebelius promoted the benefits of the Affordable Care Act and sought to draw a distinction between the plan for Medicare embodied in the ACA and that advanced by Republican presidential candidate Mitt Romney.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts